Who is sponsoring NCT00002087?

NCT00002087 is sponsored by Pharmacia and Upjohn.

What condition does NCT00002087 study?

NCT00002087 studies HIV Infections.

What drugs are being tested in NCT00002087?

Interventions: Alvircept sudotox.

What is the status of NCT00002087?

NCT00002087 is currently COMPLETED.

Last reviewed 2005-06-23 · How we verify

Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals

NCT00002087 Phase 1 COMPLETED

To investigate the safety and tolerance of an increasing number of infusions per week of alvircept sudotox ( sCD4-PE40; soluble CD4-Pseudomonas exotoxin ) at a fixed dose when administered to HIV-1-infected individuals. To investigate the effect of sCD4-PE40 on the following parameters: T lymphocyte subsets, plasma HIV RNA and cellular HIV proviral DNA in PBMC and CD4 cells, p24 levels, serum beta-2 microglobulin, and neopterin levels.

Details

Lead sponsor	Pharmacia and Upjohn
Phase	Phase 1
Status	COMPLETED

Conditions

HIV Infections

Interventions

Alvircept sudotox

Countries

United States